title: Study of cosurfactant effect on nanoemulsifying area and development of lercanidipine loaded (SNEDDS) self nanoemulsifying drug delivery system.
abstract: The present study deals with the development and characterization of self-nanoemulsifying drug delivery system (SNEDDS) to improve the oral bioavailability of poorly soluble third generation calcium channel blocker lercanidipine (LER). Solubility of the LER was estimated in various oils, cosurfactants and surfactants which were grouped into two different combinations to construct pseudoternary phase diagrams. Various thermodynamic stability and dispersibility tests were performed on the formulations from phase diagram. After constructing phase diagram of two different combinations NL-I and NL-II, the effect of cosurfactants on the nanoemulsifying area was studied and the effect of number and length of hydrophobic alkyl chains of cosurfactant in its emulsification capacity was proved. Percentage transmittance, emulsification time, viscosity and droplet size analysis were used to characterize optimized formulations. The optimized formulation composed of Cremophor EL (45% wt/wt), (13.5% wt/wt) Caproyl 90 with (1.5% wt/wt) Transcutol® HP as per limits of inactive ingredients guidelines of FDA and Maisine oil (10% wt/wt). The mean droplet size in selected nanocarrier system was 20.01 nm. The in vitro dissolution profile of LER SNEDDS was found significant in comparison to the marketed LER (Zanidip) tablet and pure drug in pH 1.2, 4.5 and 6.8 buffers. Empty hard gelatin capsule shells were filled using Pfizer's Licap technology and charged on stability conditions of 30 °C/65% RH, 40 °C/65%RH and 50 °C/75% in glass bottles where no significant degradation (p>0.05) was observed in 3 months. The results indicate that SNEDDS of LER, owing to nanosized, has potential to enhance the absorption of drug.
authors.affiliation: Department of Pharmaceutics, Faculty of Pharmacy, Hamdard University, Hamdard Nagar, New Delhi 110062, India.
authors.forename: Nitin
authors.initials: N
authors.lastname: Parmar
authors.forename: Neelam
authors.initials: N
authors.lastname: Singla
authors.forename: Saima
authors.initials: S
authors.lastname: Amin
authors.forename: Kanchan
authors.initials: K
authors.lastname: Kohli
mesh_terms: D000284:Administration, Oral; D001682:Biological Availability; D002121:Calcium Channel Blockers / Q000737:chemistry*; D002214:Capsules; D002626:Chemistry, Pharmaceutical; D004095:Dihydropyridines / Q000737:chemistry*; D004339:Drug Compounding / Q000379:methods*; D016503:Drug Delivery Systems / Q000379:methods*; D004355:Drug Stability; D045703:Emulsifying Agents / Q000737:chemistry* / Q000494:pharmacology; D005079:Excipients / Q000737:chemistry; D046529:Microscopy, Electron, Transmission; D053758:Nanoparticles / Q000737:chemistry; D009821:Oils / Q000737:chemistry; D010316:Particle Size; D012995:Solubility / Q000187:drug effects; D014783:Viscosity / Q000187:drug effects
chemical_list: D002121:Calcium Channel Blockers; D002214:Capsules; D004095:Dihydropyridines; D045703:Emulsifying Agents; D005079:Excipients; D009821:Oils; C060343:lercanidipine